China is the world's largest market for regulated stem cell therapy — and the only place many programs are legally available to international patients. Here's what licensed hospitals actually offer for type 1 and type 2 diabetes, what it really costs, and how to avoid the hype.
7-page PDF — what's actually approved (21 pilot-zone projects), published prices, who qualifies, visa routes, and what "all-in" really means.
Updated August 2026. Stem cell therapy is one of the most searched — and most abused — categories in medical tourism. The good news: China's regulatory framework (NMPA + the Hainan Boao Lecheng pilot zone) has created a legitimate, licensed pathway that treats international patients. The bad news: most English-language brokers don't use it. Here's the honest picture.
Licensed stem cell programs in China operate under two frameworks:
For diabetes specifically, the current evidence base centers on:
Short version: no stem cell product for diabetes has NMPA marketing approval as of 2026 — in China or anywhere else. What exists is a licensed clinical framework: NMPA-regulated trials and NHC-supervised investigator-initiated studies at designated Grade 3A hospitals, plus the Boao Lecheng pilot zone. Eligibility is decided by the treating team on residual beta-cell function — not by any clinic's marketing page.
| Eligibility factor | Typical requirement | Why it matters |
|---|---|---|
| Residual beta-cell function | Measurable C-peptide; duration usually 1–15 years | Programs aim to reduce insulin dependence, not replace it |
| HbA1c | Usually 7.5–12% at screening | Baseline for measured outcomes |
| Age | 18–70 (varies by protocol) | Trial/protocol inclusion criteria |
| Organ function | Normal or near-normal kidney & liver | Safety screening |
| Exclusions | Active cancer, severe CVD, active infection, pregnancy | Standard clinical exclusions |
Why some protocols carry no price: we publish a cost figure only for interventions that are NMPA-approved, or delivered inside a registered clinical trial with documented indication, eligibility criteria and informed consent. Where we cannot verify that, we quote nothing — because a price implies the thing is available to buy. Ask any clinic: “Is this NMPA-approved, or under an NMPA-registered trial?” If neither, walk away.
Criteria above are typical published protocol ranges — final eligibility is the treating physician's call on your records. A free eligibility review is the first step. Not sure where you stand? Take the free 2-minute eligibility quiz →
| Program | Typical all-in range | What's included |
|---|---|---|
| Type 1 diabetes stem cell program | Not offered as a purchasable package — NMPA-registered trial or licensed pilot-zone enrolment only, subject to documented eligibility | Hospital, physician, cell product, nursing, room, translation, coordination |
| Type 2 diabetes program | Not offered as a purchasable package — NMPA-registered trial or licensed pilot-zone enrolment only, subject to documented eligibility | Hospital, physician, cell product, nursing, room, translation, coordination |
| Eligibility workup (pre-travel) | $800–2,000 | Records review, remote physician consult, screening labs |
| Follow-up program (12 months) | $2,000–5,000 | Remote monitoring, telehealth consults, lab coordination |
Compare: US stem cell clinics routinely charge $50,000–150,000 for unproven, FDA-unsanctioned treatments with zero regulatory oversight. China's licensed Boao pathway operates under a real regulatory framework with a real hospital behind it — and we publish no price for it.
These are the ranges international patients actually encounter, by market. Our own published pricing is included for direct comparison; competitor figures are publicly reported ranges and should be verified with the provider before committing.
| Market / program | Typical range (USD) | Regulatory status |
|---|---|---|
| China — Boao Lecheng, VCC network programs | Enrolment only — no packaged price; quote issued per case after eligibility review | Licensed pilot-zone protocols, Grade 3A hospitals, escrowed payment |
| China — other broker listings (Boao) | $15,000–35,000 | Same zone — verify hospital and protocol before comparing prices |
| United States | Not commercially available | FDA has approved no MSC therapy for diabetes; Phase III trials (e.g. Vertex VX-880) are free but strictly eligibility-limited |
| Switzerland / Germany | $40,000–80,000 | Varies; some clinics operate under compassionate-use rules |
| Mexico (Tijuana / Monterrey) | $8,000–20,000 | Largely unregulated; no mandatory outcome tracking |
| Thailand | $12,000–25,000 | Semi-regulated; oversight varies by hospital |
Why the table reads this way: China's licensed Boao pathway sits mid-market on price but top on regulatory structure — cheaper than unproven US clinics and Western Europe, more expensive than unregulated Mexico. The difference is a documented, escrowed, hospital-signed protocol. And on the "$12,000–18,000" numbers you'll see on broker pages: we do not publish a price for this protocol, and neither should anyone who has not established that the treatment itself is available. Treat any specific quote, low or high, as a cue to verify the hospital, the protocol and its regulatory status. That is the question that matters, not the number.
China's Hainan Free Trade Port and the Boao Lecheng International Medical Tourism Pilot Zone are the government-designated venue for advanced licensed therapies. Key facts:
We only coordinate with zone-licensed hospitals with JCI or equivalent accreditation, English-speaking international departments, and documented experience with foreign patients. Every hospital is verified before it enters our network.
Stem cell tourism has a well-earned reputation problem — largely because patients wire six figures to unlicensed clinics that vanish. Our structure:
Because results are documented against the treatment agreement and every published outcome is tied to a verified case file with patient consent, our track record grows in credibility over time. That's the moat — and it's why we publish what programs can and cannot do.
Yes — in licensed facilities under the NMPA clinical-trial framework or the Boao Lecheng pilot zone's licensed-treatment framework. We do not coordinate with unlicensed clinics, and we will tell you if a program you found online is not licensed.
No — as of 2026 no stem cell product for diabetes has NMPA marketing approval anywhere, including China. Treatment happens under licensed trial or pilot-zone frameworks. Anyone claiming "NMPA-approved diabetes stem cell treatment" is misstating the regulatory status.
Usually because the setting is unregulated (parts of Mexico) or the figure is a broker-published average that doesn't match licensed hospital pricing. Licensed Boao programs are quoted per case, after eligibility review. Verify the hospital registry before comparing prices.
If you meet inclusion criteria — measurable residual C-peptide, age and organ-function limits — trial enrollment can reduce or waive treatment cost, but you bear travel and stay costs and must meet strict criteria. We can walk through both paths in your free review.
No licensed program requires you to stop insulin. Programs aim to reduce dependence over time under medical supervision. Anyone who tells you to stop insulin before or during treatment should be a red flag.
Typically 2–4 weeks for the initial program, depending on the protocol. Follow-up is remote for up to 12 months.
We publish reviews only from completed, verified cases — each tied to a treatment contract, confirmed with the hospital, and published with the patient's consent. Fabricated reviews would breach our escrow terms. Until a case completes and a patient consents, we don't publish testimonials — the published pricing, escrow mechanics, and written agreements are the proof points you can verify today.
Describe your case and current treatment. We'll respond within one business day.
💬 Get your estimate on WhatsApp — usually replies within minutes